Kinase inhibitors are a class of targeted cancer therapies designed to block the activity of specific kinases. These inhibitors can be highly effective in cancers driven by particular kinase mutations. For instance, Imatinib (Gleevec) targets the BCR-ABL fusion protein in CML, while Erlotinib (Tarceva) inhibits mutated EGFR in certain lung cancers.
